Safety and PK of STSA-1005 in Healthy Subjects

Phase 1, randomised, double-blind trial of STSA-1005 in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (4 cohorts), sponsored by Staidson Biopharmaceutical. Primary endpoint: Incidence of Adverse Events, Serious Adverse Events, Clinically Significant Laboratory Abnormalities, Electrocardiogram Abnormalities, Vital Signs Abnormalities and Physical Examination Abnormalities. Started Oct 2021; status: completed.